An observation on inappropriate probiotic subgroup classifications in the meta-analysis by Lau and Chamberlain

International Journal of General Medicine

Volumn 9, Issue , 2016, Pages 333-335

  McFarland, Lynne V ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

BIFIDOBACTERIUM BIFIDUM; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; HUMAN; INAPPROPRIATE PRESCRIBING; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LETTER; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SACCHAROMYCES BOULARDII;

EID: 84992013350     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S119970     Document Type: Letter

References (19)

1. Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and metaanalysis. Int J Gen Med. 2016;9:27–37.
2. Hill C, Guarner F, Reid G, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514.
3. McFarland LV. Importance of subgroup analysis in probiotic metaanalyses. Letter to the Editor. Br J Nutr. 2016;116:375–376.
4. Auclair J, Frappier M, Millette M. Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2 (Bio-K+): characterization, manufacture, mechanisms of action and quality control of a specific probiotic combination for primary prevention of Clostridium difficile infections. CID. 2015;60(suppl 2):S135–S144.
5. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibioticassociated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989; 96:981–988.
6. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of -lactam-associated diarrhea by Saccharomyces boulardii compared to placebo. Am J Gastroenterol. 1995;90:439–448.
7. Duman DG, Bor S, Ozütemiz O, et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol. 2005;17(12):1357–1361.
8. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Alimentary Pharmacology and Therapeutics. 2005;21(5):583–590.
9. Can M, Beirbellioglu BA, Avci IY, Beker CM, Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibioticassociated diarrhea: a prospective study. Med Sci Monit. 2006;12(4): 119–122.
10. Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107(6):922–931.
11. Shan L, Hou P, Wang Z, et al. Prevention and treatment of diarrhea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Beneficial Microbes. 2013;4(4):329–334.
12. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999;104(5):e64.
13. Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc. 2001;76: 883–889.
14. Miller M, Florencio S, Eastmond J, Reynolds S. Results of 2 prospective randomized studies of Lactobacillus GG to prevent C. difficile infection in hospitalized adults receiving antibiotics. Abstract of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2008;48:578–579.
15. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol. 2004;7:59–62.
16. Rafiq R. Prevention of Clostridium difficile (C. difficile) diarrhea with probiotic in hospitalized patients treated with antibiotics. Gastroenterol. 2007:132(4):187. Abstract S1167.
17. Beausoleil M, Fortier N, Guénette S, et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, doubleblind, placebo-controlled trial. Can J Gastroenterology. 2007;21(11): 732–736.
18. Sampalis J, Psaradellis E, Rampakakis E. Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea –a placebo controlled double-blind randomized, multi-center study. Arch Med Sci. 2010;6(1): 56–64.
19. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010;105(7):1636–1641.